ID

31335

Description

MLN8237 for Treatment of Patients With Ovarian, Fallopian Tube, or Peritoneal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00853307

Link

https://clinicaltrials.gov/show/NCT00853307

Keywords

Versions (1)
  1. 8/14/18 8/14/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

August 14, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Ovarian Carcinoma NCT00853307

English

Eligibility Ovarian Carcinoma NCT00853307

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. female patients 18 years or older
Description

Gender | Age

Data type

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
2. histologically or cytologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Description

Epithelial ovarian cancer | Fallopian Tube Carcinoma | Primary peritoneal carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C0677886
UMLS CUI [2]
C0238122
UMLS CUI [3]
C1514428
3. eastern cooperative oncology group performance status 0 or 1
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
4. postmenopausal at least 1 year, or
Description

Postmenopausal state

Data type

boolean

Alias
UMLS CUI [1]
C0232970
surgically sterile, or
Description

Female Sterilization

Data type

boolean

Alias
UMLS CUI [1]
C0015787
if childbearing potential, agree to 2 effective methods of nonhormonal contraception, or agree to completely abstain from heterosexual intercourse
Description

Childbearing Potential Contraceptive methods | Exception Hormonal contraception | Childbearing Potential Sexual Abstinence

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C2985296
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C0036899
5. able to provide written informed consent.
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
6. within 7 days before study:
Description

Status pre- Clinical Trial

Data type

boolean

Alias
UMLS CUI [1,1]
C0332152
UMLS CUI [1,2]
C0008976
absolute neutrophils (anc) ≥ 1,500/μl
Description

Absolute neutrophil count

Data type

boolean

Alias
UMLS CUI [1]
C0948762
platelets ≥100,000/ μl
Description

Platelet Count measurement

Data type

boolean

Alias
UMLS CUI [1]
C0032181
total bilirubin must be < 1.5 times upper limit of the normal (uln)
Description

Serum total bilirubin measurement

Data type

boolean

Alias
UMLS CUI [1]
C1278039
alanine aminotransferase (alt) or aspartate aminotransferase (ast) must be ≤ 2.5 times the uln. ast and alt may be elevated up to 5 times the uln if ascribed to metastatic liver disease.
Description

Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Aspartate aminotransferase increased | Alanine aminotransferase increased | Relationship Secondary malignant neoplasm of liver

Data type

boolean

Alias
UMLS CUI [1]
C0201836
UMLS CUI [2]
C0201899
UMLS CUI [3]
C0151904
UMLS CUI [4]
C0151905
UMLS CUI [5,1]
C0439849
UMLS CUI [5,2]
C0494165
creatinine clearance ≥ 30 ml/minute
Description

Creatinine clearance measurement

Data type

boolean

Alias
UMLS CUI [1]
C0373595
7. platinum-refractory or -resistant disease
Description

Platinum Refractory Disease | Disease Resistant Platinum

Data type

boolean

Alias
UMLS CUI [1,1]
C0032207
UMLS CUI [1,2]
C1514815
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C0332325
UMLS CUI [2,3]
C0032207
8. measurable disease by response evaluation criteria in solid tumors (recist) or ca 125 level of > 40 units/ml and clinical evidence disease
Description

Measurable Disease | CA 125 measurement | Evidence Clinical Disease

Data type

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2]
C0201549
UMLS CUI [3,1]
C3887511
UMLS CUI [3,2]
C0205210
UMLS CUI [3,3]
C0012634
9. recovered from effects of prior therapy
Description

Effects of Prior Therapy Patient recovered

Data type

boolean

Alias
UMLS CUI [1,1]
C1704420
UMLS CUI [1,2]
C1514463
UMLS CUI [1,3]
C1115804
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. pregnant or lactating
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
2. serious illness that could interfere with protocol completion
Description

Illness Serious Interferes with Completion of clinical trial

Data type

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0521102
UMLS CUI [1,4]
C2732579
3. investigational treatment 28 days prior to first dose.
Description

Therapy, Investigational

Data type

boolean

Alias
UMLS CUI [1]
C0949266
4. maximum 4 prior systemic therapies: 2 platinum-based, 1 nonplatinum cytotoxic, 1 biological
Description

Systemic therapy Quantity Maximum | Systemic therapy Platinum-Based Quantity | Systemic therapy cytotoxic Quantity | Systemic therapy biological Quantity

Data type

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0806909
UMLS CUI [2,1]
C1515119
UMLS CUI [2,2]
C1514162
UMLS CUI [2,3]
C1265611
UMLS CUI [3,1]
C1515119
UMLS CUI [3,2]
C1511636
UMLS CUI [3,3]
C1265611
UMLS CUI [4,1]
C1515119
UMLS CUI [4,2]
C0205460
UMLS CUI [4,3]
C1265611
5. known central nervous system metastases
Description

CNS metastases

Data type

boolean

Alias
UMLS CUI [1]
C0686377
6. prior allogeneic bone marrow or organ transplantation
Description

Allogeneic bone marrow transplantation | Organ Transplantation Allogeneic

Data type

boolean

Alias
UMLS CUI [1]
C0149615
UMLS CUI [2,1]
C0029216
UMLS CUI [2,2]
C1515895
7. radiotherapy within 21 days prior to first dose
Description

Therapeutic radiology procedure

Data type

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0005953
UMLS CUI [1,3]
C0439165
8. radiotherapy to > 25% bone marrow
Description

Therapeutic radiology procedure Bone Marrow Percentage

Data type

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0005953
UMLS CUI [1,3]
C0439165
9. major surgery, infection requiring systemic antibiotic therapy within 14 days prior to first dose
Description

Major surgery | Communicable Disease Requirement Antibiotic therapy Systemic

Data type

boolean

Alias
UMLS CUI [1]
C0679637
UMLS CUI [2,1]
C0009450
UMLS CUI [2,2]
C1514873
UMLS CUI [2,3]
C0338237
UMLS CUI [2,4]
C0205373
10. inability to swallow orally administered medication
Description

Lacking Able to swallow Oral medication

Data type

boolean

Alias
UMLS CUI [1,1]
C0332268
UMLS CUI [1,2]
C2712086
UMLS CUI [1,3]
C0175795
11. diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected
Description

Cancer Other | Exception Skin carcinoma | Exception Complete excision Carcinoma in Situ

Data type

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0699893
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0015250
UMLS CUI [3,3]
C0007099
12. known history of human immunodeficiency virus (hiv) infection, hepatitis b, or hepatitis c.
Description

HIV Infection | Hepatitis B | Hepatitis C

Data type

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0019163
UMLS CUI [3]
C0019196
Back to the top of the page

Similar models

Eligibility Ovarian Carcinoma NCT00853307

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Gender | Age
Item
1. female patients 18 years or older
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Epithelial ovarian cancer | Fallopian Tube Carcinoma | Primary peritoneal carcinoma
Item
2. histologically or cytologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
boolean
C0677886 (UMLS CUI [1])
C0238122 (UMLS CUI [2])
C1514428 (UMLS CUI [3])
ECOG performance status
Item
3. eastern cooperative oncology group performance status 0 or 1
boolean
C1520224 (UMLS CUI [1])
Postmenopausal state
Item
4. postmenopausal at least 1 year, or
boolean
C0232970 (UMLS CUI [1])
Female Sterilization
Item
surgically sterile, or
boolean
C0015787 (UMLS CUI [1])
Childbearing Potential Contraceptive methods | Exception Hormonal contraception | Childbearing Potential Sexual Abstinence
Item
if childbearing potential, agree to 2 effective methods of nonhormonal contraception, or agree to completely abstain from heterosexual intercourse
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C2985296 (UMLS CUI [2,2])
C3831118 (UMLS CUI [3,1])
C0036899 (UMLS CUI [3,2])
Informed Consent
Item
5. able to provide written informed consent.
boolean
C0021430 (UMLS CUI [1])
Status pre- Clinical Trial
Item
6. within 7 days before study:
boolean
C0332152 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
Absolute neutrophil count
Item
absolute neutrophils (anc) ≥ 1,500/μl
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelets ≥100,000/ μl
boolean
C0032181 (UMLS CUI [1])
Serum total bilirubin measurement
Item
total bilirubin must be < 1.5 times upper limit of the normal (uln)
boolean
C1278039 (UMLS CUI [1])
Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Aspartate aminotransferase increased | Alanine aminotransferase increased | Relationship Secondary malignant neoplasm of liver
Item
alanine aminotransferase (alt) or aspartate aminotransferase (ast) must be ≤ 2.5 times the uln. ast and alt may be elevated up to 5 times the uln if ascribed to metastatic liver disease.
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0151904 (UMLS CUI [3])
C0151905 (UMLS CUI [4])
C0439849 (UMLS CUI [5,1])
C0494165 (UMLS CUI [5,2])
Creatinine clearance measurement
Item
creatinine clearance ≥ 30 ml/minute
boolean
C0373595 (UMLS CUI [1])
Platinum Refractory Disease | Disease Resistant Platinum
Item
7. platinum-refractory or -resistant disease
boolean
C0032207 (UMLS CUI [1,1])
C1514815 (UMLS CUI [1,2])
C0012634 (UMLS CUI [2,1])
C0332325 (UMLS CUI [2,2])
C0032207 (UMLS CUI [2,3])
Measurable Disease | CA 125 measurement | Evidence Clinical Disease
Item
8. measurable disease by response evaluation criteria in solid tumors (recist) or ca 125 level of > 40 units/ml and clinical evidence disease
boolean
C1513041 (UMLS CUI [1])
C0201549 (UMLS CUI [2])
C3887511 (UMLS CUI [3,1])
C0205210 (UMLS CUI [3,2])
C0012634 (UMLS CUI [3,3])
Effects of Prior Therapy Patient recovered
Item
9. recovered from effects of prior therapy
boolean
C1704420 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C1115804 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
1. pregnant or lactating
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Illness Serious Interferes with Completion of clinical trial
Item
2. serious illness that could interfere with protocol completion
boolean
C0221423 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C2732579 (UMLS CUI [1,4])
Therapy, Investigational
Item
3. investigational treatment 28 days prior to first dose.
boolean
C0949266 (UMLS CUI [1])
Systemic therapy Quantity Maximum | Systemic therapy Platinum-Based Quantity | Systemic therapy cytotoxic Quantity | Systemic therapy biological Quantity
Item
4. maximum 4 prior systemic therapies: 2 platinum-based, 1 nonplatinum cytotoxic, 1 biological
boolean
C1515119 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0806909 (UMLS CUI [1,3])
C1515119 (UMLS CUI [2,1])
C1514162 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C1515119 (UMLS CUI [3,1])
C1511636 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C1515119 (UMLS CUI [4,1])
C0205460 (UMLS CUI [4,2])
C1265611 (UMLS CUI [4,3])
CNS metastases
Item
5. known central nervous system metastases
boolean
C0686377 (UMLS CUI [1])
Allogeneic bone marrow transplantation | Organ Transplantation Allogeneic
Item
6. prior allogeneic bone marrow or organ transplantation
boolean
C0149615 (UMLS CUI [1])
C0029216 (UMLS CUI [2,1])
C1515895 (UMLS CUI [2,2])
Therapeutic radiology procedure
Item
7. radiotherapy within 21 days prior to first dose
boolean
C1522449 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
Therapeutic radiology procedure Bone Marrow Percentage
Item
8. radiotherapy to > 25% bone marrow
boolean
C1522449 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
Major surgery | Communicable Disease Requirement Antibiotic therapy Systemic
Item
9. major surgery, infection requiring systemic antibiotic therapy within 14 days prior to first dose
boolean
C0679637 (UMLS CUI [1])
C0009450 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C0338237 (UMLS CUI [2,3])
C0205373 (UMLS CUI [2,4])
Lacking Able to swallow Oral medication
Item
10. inability to swallow orally administered medication
boolean
C0332268 (UMLS CUI [1,1])
C2712086 (UMLS CUI [1,2])
C0175795 (UMLS CUI [1,3])
Cancer Other | Exception Skin carcinoma | Exception Complete excision Carcinoma in Situ
Item
11. diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0015250 (UMLS CUI [3,2])
C0007099 (UMLS CUI [3,3])
HIV Infection | Hepatitis B | Hepatitis C
Item
12. known history of human immunodeficiency virus (hiv) infection, hepatitis b, or hepatitis c.
boolean
C0019693 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial